← Oncology Approval Tracker

FDA DECISION ·

Tecvayli

teclistamab-cqyv · Janssen Biotech

FDA approvalNew dosing regimenMultiple myeloma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Optional 1.5 mg/kg every two weeks for patients in the approved relapsed or refractory multiple myeloma setting who maintain complete response or better for at least six months.

LAMPGEN ANALYSIS

Why it matters

The approved interval can reduce treatment visits for patients who meet the sustained response criterion.

What research teams should watch

Confirm the response start date and duration before changing the orders, and preserve infection and immunoglobulin follow-up.

PRIMARY RECORDS

Sources